Keywords: Roche, Ipsen, Taspoglutide, Merck & Co, Januvia, Research
Roche/Ipsen’s taspoglutide meets Ph III endpoints, beating Merck & Co’s Januvia
Article | 04 December 2009
Results from two further Phase III clinical trials show that Swiss pharmaceutical major Roche’s diabetes drug candidate, once-weekly taspoglutide, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
